September 2014

New Product - Stribild

Stribild (tenofovir disoproxil fumarate/ emtricitabine/ elvitegravir/ cobicistat) contains combination NRTIs + integrase strand transfer inhibitor (INSTI) + pharmacokinetic enhancer respectively. Stribild is indicated as a single tablet regimen for HIV infection in treatment naive adults. It is contraindicated with concomitant alfuzosin, rifampicin, ergot derivatives (eg dihydroergotamine, ergonovine, ergotamine, methylergonovine), cisapride, St John's wort, lovastatin, simvastatin, pimozide, sildenafil for PAH, oral midazolam, triazolam, other products containing same active components (tenofovir disoproxil fumarate, emtricitabine), ritonavir, lamivudine, adefovir dipivoxil. Stribild is also contraindicated in children and adolescents aged less than 18 yrs. Stribild is available as a combination tablet containing tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, elvitegravir 150 mg, cobicistat 150 mg in packs of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au